Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Overweight rating on the shares. The firm updated estimates following the recent Eylea biosimilar ...

This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a report released on Monday ...

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by JP Morgan on June 9, 2025. The analyst firm set a price target for $800.00 expecting REGN to rise to within 12 ...

Ulta Beauty ( ULTA) was the best-performing stock in the S&P 500 after the beauty products retailer beat profit and sales ...